VX-828 / Vertex - LARVOL DELTA

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov) - P1 | N=165 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed

Trial completion • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

VX25-828-101: Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis (clinicaltrialsregister.eu) - P1/2 | N=55 | Not yet recruiting | Sponsor: Vertex Pharmaceuticals Inc.

New P1/2 trial • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis (clinicaltrials.gov) - P1 | N=165 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting | N=255 ➔ 165

Enrollment change • Enrollment closed • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases